Array BioPharma Inc. (NASDAQ:ARRY)’s share price fell 1.7% on Tuesday . The company traded as low as $3.39 and last traded at $3.39, with a volume of 866,780 shares traded. The stock had previously closed at $3.45.

A number of research firms have weighed in on ARRY. Cantor Fitzgerald reiterated a “buy” rating on shares of Array BioPharma in a research report on Wednesday, May 4th. Jefferies Group reiterated a “buy” rating on shares of Array BioPharma in a research report on Wednesday, May 4th. Piper Jaffray Cos. set a $7.00 price target on shares of Array BioPharma and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Zacks Investment Research lowered shares of Array BioPharma from a “buy” rating to a “hold” rating in a research report on Monday, August 8th. Finally, Leerink Swann reiterated a “buy” rating and issued a $6.00 price target on shares of Array BioPharma in a research report on Thursday, May 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Array BioPharma presently has an average rating of “Buy” and a consensus price target of $7.50.

The company’s market capitalization is $484.82 million. The firm has a 50-day moving average price of $3.73 and a 200 day moving average price of $3.25.

Array BioPharma (NASDAQ:ARRY) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.02. The business had revenue of $43.20 million for the quarter, compared to analyst estimates of $41.51 million. The company’s revenue for the quarter was up 251.2% on a year-over-year basis. During the same period last year, the firm posted ($0.09) EPS. Equities research analysts expect that Array BioPharma Inc. will post ($0.68) EPS for the current year.

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.